Prognostic Value of -Pertechnetate Thyroid Scintigraphy in Radioiodine Therapy in a Cohort of Chinese Graves’ Disease Patients: A Pilot Clinical Study

Table 1

Pre-RIT laboratory and clinical characteristics of patients.

Variables	Values
Gender
Male	41 (34.75%)
Female	77 (65.25%)
Age (years)	40.35 ± 12.69 (17–77)
Disease duration (years)	4.20 ± 4.80 (0.08–30)
Ophthalmopathy
Yes	73 (61.86%)
No	45 (38.14%)
Hormone levels of pre-RIT
FT4 (pmol/L)	55.63 ± 27.19 (22.71–140.08)
FT3 (pmol/L)	19.99 ± 7.36 (7.46–44.39)
TT4 (nmol/L)	260.62 ± 80.07 (16.7–387.31)
TT3 (nmol/L)	7.08 ± 2.99 (1.01–12.32)
Thyroid mass of pre-RIT (g)	41.13 ± 8.85 (22.68–61.60)
Thyroid ^99mTc-pertechnetate uptake of pre-RIT (%)	15.23 ± 7.59 (2.80–36.80)
Outcome of post-RIT
Hypothyroidism	35 (29.66%)
Euthyroidism	49 (41.53%)
Hyperthyroidism	34 (28.81%)

All values are expressed as mean ± SD for continuous variables and as the number of patients (percentage) for categorical variables.